Bariatric Surgeries and Glucose Homeostasis During a Mixed Meal Test (BASMEAL)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Bariatric surgery can lead to improvement or even resolution of type 2 diabetes Mellitus (T2DM) with the spectrum of responses depending also on operation procedures. However, many mechanisms of metabolic action of different surgical techniques still are unclear.
The aim of this study is to provide a better understanding of the effects of three types of bariatric surgery (lap banding, gastric bypass and sleeve gastrectomy) on beta-cell function and incretin secretion. A mixed meal tolerance (MMT) test will be performed before and 1 and 12 months after surgery to assess beta cell adequacy and glucagon-like-peptide-1 (GLP1)/glucose-dependent insulinotropic polypeptide (GIP) bioavailability.
| Condition | Intervention |
|---|---|
|
Obesity |
Procedure: Roux-en-Y-gastric bypass Procedure: laparoscopic adjustable gastric banding Procedure: laparoscopic sleeve gastrectomy Other: diet treatment |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | Effects of Bariatric Surgeries on Glucose Homeostasis and Its Determinants During a Mixed Meal Tolerance Test |
- change in glucose response (pAUC) to mixed meal test between baseline and 1 month after undergoing bariatric surgery or being put on low calorie diet [ Time Frame: 1 month ] [ Designated as safety issue: No ]Blood samples will be taken at basal (-20',-10' and 0'), and after the ingestion of a standardized mixed meal (+10', +20', +30',+45', +60', +75', +90', +105', +120', +140', +160', +180', +200', +220', +240', +270', +300').
- change in glucose response (pAUC) to mixed meal test between baseline and 12 months after undergoing bariatric surgery or being put on low calorie diet [ Time Frame: 12 months ] [ Designated as safety issue: No ]Blood samples will be taken at basal(-20',-10' and 0'), and after the ingestion of a standardized mixed meal (+10', +20', +30',+45', +60', +75', +90', +105', +120', +140', +160', +180', +200', +220', +240', +270', +300').
- changes in β-cell response mixed meal test between baseline and 1 and 12 months after undergoing bariatric surgery or being put on low calorie diet [ Time Frame: 1 month and 12 months ] [ Designated as safety issue: No ]Beta-cell function will be assessed by a state of art mathematical model applied to glucose and C-peptide curves during a standardized mixed meal. Two main metrics of beta cell function will be derived from modeling: 1) derivative or dynamic control of beta cell function, and 2) proportional or static control of beta cell function.
- changes in active GLP1 systemic bioavailability during a mixed meal test between baseline and 1 or 12 months after undergoing bariatric surgery or being put on low calorie diet. [ Time Frame: 1 month and 12 months ] [ Designated as safety issue: No ]Blood samples will be taken at basal(-20',-10' and 0'), and after the ingestion of a standardized mixed meal (+10', +20', +30',+45', +60', +75', +90', +105', +120', +140', +160', +180', +200', +220', +240', +270', +300').
- change in HbA1c between baseline and 1 or 12 months after undergoing bariatric surgery or being put on low calorie diet. [ Time Frame: 1 month and 12 months ] [ Designated as safety issue: No ]high pressure liquid chromatography (HPLC) method
Biospecimen Retention: Samples Without DNA
serum, plasma
| Estimated Enrollment: | 64 |
| Study Start Date: | February 2013 |
| Estimated Study Completion Date: | June 2016 |
| Estimated Primary Completion Date: | December 2015 (Final data collection date for primary outcome measure) |
| Groups/Cohorts | Assigned Interventions |
|---|---|
|
Roux-en-Y-gastric bypass
morbidly obese subjects undergoing gastric bypass surgery
|
Procedure: Roux-en-Y-gastric bypass
Gastric bypass consisted of creation of a 15-20 ml gastric pouch, a 150 cm Roux limb, and a 50 cm biliopancreatic limb
Other Name: RYGB
|
|
gastric banding
morbidly obese subjects undergoing laparoscopic adjustable gastric banding
|
Procedure: laparoscopic adjustable gastric banding
Gastric banding functions by limiting food intake after the placement of an inflatable tube around the stomach just below the gastroesophageal junction, which allows for adjustment of the size of the outlet via the addition or removal of saline through a subcutaneous port.
Other Name: LAGB
|
|
sleeve gastrectomy
morbidly obese subjects undergoing laparoscopic sleeve gastrectomy
|
Procedure: laparoscopic sleeve gastrectomy
Sleeve gastrectomy involved a gastric reduction of 75 to 80% by resecting the stomach alongside a 30-French endoscope beginning 3 cm from pylorus and ending at the angle of His
Other Name: SG
|
|
control group
morbidly obese subjects not undergoing bariatric surgery, on diet treatment
|
Other: diet treatment
Hypocaloric diet providing a 1000 Kcal/d deficit from total energy expenditure assessed by indirect calorimetry and physical activity determination
Other Name: diet
|
Detailed Description:
The effects of different kind of bariatric surgery on glucose homeostasis and its primary determinants (insulin sensitivity and secretion) may differ from one procedure to another. In spite being able to promote improvement/resolution of T2DM, many mechanisms of metabolic action of weight-loss surgery are still unclear. It has been hypothesized that changing the nutrient route through the gut may be a key factor in changing beta cell function and/or insulin sensitivity.
In this study a mixed meal test will be used to assess changes in glucose regulation, beta cell function and incretin bioavailability brought about by different bariatric surgeries in obese patients.
All participants will ingest a standardized mixed meal (163 Kcal; 57% carbohydrate, 33% fat, 22% prot) and will be monitored for 300 minutes thereafter.
Baseline (-20', -10', 0') blood samples will be collected to measure plasma glucose, insulin, C-peptide, incretins and the 13-Carbon-glucose/12-Carbon-glucose (13C-/12C-glucose) ratio (the last one by isotope ratio mass spectrometry).
At time 0', subjects will ingest a standardized mixed meal containing 30 g corn flour and 20 g cheese (parmesan) over 20 minutes. Plasma glucose, insulin, C-peptide, GLP1/GIP and the 13C-/12C-glucose ratio will be assessed at +10', +20', +30', +45', +60', +75', +90', +105', +120', +140', +160', +180', +200', +220', +240', +270', +300'.
Blood samples will be quickly spun at 1500 g at +4°C, plasma/serum will be collected and stored at -80°C.
The 13-Carbon content of maize starch is higher than most of non maize derived sugars. Thus, in individuals on maize and cane sugar free diets, the 13-Carbon/12-Carbon (13C/12C) maize starch ratio is higher (about 10:1000) than the 13C/12C ratio of endogenous glucose derived from glycogenolysis/gluconeogenesis. When these individuals ingest maize starch, the glucose molecules appearing in the systemic circulation which are derived from maize starch will display a 13C-/12C ratio which is identical to maize starch and higher than endogenous glucose. Thus, by measuring the time course of plasma 13C-/12C-glucose ratio, it will be possible to distinguish meal derived glucose from endogenous glucose output (glycogenolysis and gluconeogenesis).
This mixed meal test will be performed before and 1 and 12 months after bariatric surgery. The same tests with the same timing will be performed in a control group of obese patients not undergoing bariatric surgery, being treated with diet only.
Eligibility| Ages Eligible for Study: | 18 Years to 60 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
A total of 64 morbidly obese patients will be studied, composed of:
- 16 subjects scheduled for Roux-en-Y-gastric bypass;
- 16 subjects scheduled for laparoscopic adjustable gastric banding;
- 16 subjects scheduled for laparoscopic sleeve gastrectomy;
- 16 subjects not undergoing bariatric surgery, on diet treatment (control group)
Inclusion Criteria:
- BMI > 40 kg/m2.
- BMI ≥ 35 kg/m2 and comorbidities.
- No major organ disease unrelated to excess body weight.
- Mentally able to understand the study and willingness to participate in the study
Exclusion Criteria:
- BMI< 35 kg/m2.
- pregnancy/lactation.
- prior bariatric or gastrointestinal surgery. Malignancies; mental incapacity; unwillingness or language barriers precluding adequate understanding or cooperation
Contacts and Locations| Contact: Riccardo C Bonadonna, MD, PHD | +390458123115 | riccardo.bonadonna@univr.it |
| Contact: Maria Grazia Zenti, MD | +390458123110 | mariagrazia.zenti@univr.it |
| Italy | |
| AOUI Verona | Recruiting |
| Verona, Italy, 37126 | |
| Contact: Riccardo C Bonadonna, MD, PHD +390458123115 riccardo.bonadonna@univr.it | |
| Contact: Maria Grazia Zenti, MD +390458123110 mariagrazia.zenti@univr.it | |
| Principal Investigator: Maria Grazia Zenti, MD | |
| Principal Investigator: | Maria Grazia Zenti, MD | Division of Endocrinology and Metabolic Diseases, AOUI Verona, Italy |
| Study Director: | Enzo Bonora, Professor | Division of Endocrinology and Metabolic Diseases, University Hospital of Verona |
More Information
No publications provided
| Responsible Party: | Azienda Ospedaliera Universitaria Integrata Verona |
| ClinicalTrials.gov Identifier: | NCT01767441 History of Changes |
| Other Study ID Numbers: | MGZenti MMT, MMT in bariatric surgeries |
| Study First Received: | January 11, 2013 |
| Last Updated: | February 8, 2013 |
| Health Authority: | Italy: Ethics Committee |
Keywords provided by Azienda Ospedaliera Universitaria Integrata Verona:
|
bariatric surgery gastric bypass gastric banding sleeve gastrectomy weight loss |
Type 2 Diabetes mellitus GLP1 obesity mixed meal test |
Additional relevant MeSH terms:
|
Obesity Overnutrition Nutrition Disorders |
Overweight Body Weight Signs and Symptoms |
ClinicalTrials.gov processed this record on May 21, 2013